Bioversys AG

Research Bioversys AG (BIOV) on Bullrun: market cap CHF 152.05M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBIOV
• ExchangeSW
• CountrySwitzerland
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCHF
• Market capCHF 152.05M
• Financial periodFY2025
• RevenueCHF 800.00K
• Net income-CHF 21.83M
• Free cash flow-CHF 22.16M
• Gross margin-386.6%

Valuation Snapshot

latest market cap is CHF 152.05M.

About Bioversys AG

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections.

Frequently asked questions

What is Bioversys AG's market cap?

Bioversys AG's market capitalization is CHF 152.05M.

What does Bioversys AG do?

BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections.